Tesamorelin is a synthetic analogue of growth hormone-releasing hormone consisting of the GHRH(1-44) sequence with a trans-3-hexenoyl group attached at the N-terminus. The acylation confers resistance to degradation by dipeptidyl peptidase-4, which rapidly inactivates native GHRH, and this stabilisation is the defining structural feature of the compound.
Mechanistic context
Like other GHRH analogues, tesamorelin acts at the GHRH receptor on pituitary somatotrophs to stimulate growth hormone secretion, preserving downstream feedback regulation rather than bypassing it. What distinguishes tesamorelin in the literature is the endpoint on which it was studied: visceral adipose tissue, quantified by imaging rather than inferred from anthropometric measures. This gives its clinical literature an objectivity that self-reported or surrogate endpoints lack.
Published findings
Falutz and colleagues (2007) reported metabolic effects of a growth hormone-releasing factor in patients with HIV in the New England Journal of Medicine, examining visceral fat accumulation in that population. A 2008 report from the same group addressed long-term safety and effects in HIV patients with abdominal fat accumulation, and a 2010 report described a randomised placebo-controlled trial with a safety extension.
Stanley and colleagues (2014) reported effects on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation, published in JAMA. The inclusion of hepatic fat as an endpoint extends the findings beyond visceral adipose tissue to ectopic fat deposition more broadly.
Scope and limitations of the evidence
Tesamorelin has the most developed clinical literature of any compound in this catalogue: randomised, placebo-controlled trials published in high-profile general medical journals, with imaging-based objective endpoints and reported safety extensions.
The essential limitation is population. All the cited trials were conducted in people with HIV-associated lipodystrophy, a condition with a specific pathophysiology involving antiretroviral therapy and chronic infection. Effects demonstrated in that population do not establish effects in people without it, and this constraint is frequently omitted when the compound is discussed in secondary sources.
Growth hormone axis stimulation also has known effects on glucose metabolism, and the safety extension reports address this. Any evaluation of the literature should include those metabolic findings rather than the adiposity endpoints alone.
Use in experimental design
Visceral adipose tissue quantification requires cross-sectional imaging — CT or MRI at a defined vertebral level — since waist circumference cannot distinguish visceral from subcutaneous compartments. The cited trials establish the methodology. Where glucose metabolism is monitored, fasting measures alone are insufficient to detect the changes GHRH-axis stimulation can produce, and dynamic testing is more informative.
Analytical and handling notes
Each lot is supplied with a certificate of analysis reporting RP-HPLC purity, mass identification by ESI-MS and label claim recovery, together with an independent ICP-MS elemental impurities report. Purity figures apply to the specific lot tested and should be read against the lot documentation rather than inferred from generic reference material. Storage guidance appears on the technical data sheet; the exact supplied salt form, counterion and hydration state are lot and supplier specific and should be reconciled against supplier documentation before quantitative work.
This material is supplied for laboratory research use only. It is not a drug, is not intended for human or veterinary use, and no statement above should be read as a claim of therapeutic effect.
